Recursion Pharmaceuticals (RXRX)
Builds investigational medicines through automated biology, AI chemistry, and partner programs.
Something off on this page? Send us feedback.
Develops investigational medicines through Recursion OS, an AI-native system linking automated biology, chemistry design, and clinical-development data. Revenue comes from collaboration agreements and grants rather than approved drug sales, with the pipeline focused on oncology and rare disease.
Develops investigational medicines through Recursion OS, an AI-native system that links automated data generation, proprietary biological datasets, chemistry design, compute, and clinical-development intelligence. The portfolio spans wholly owned oncology and rare-disease programs plus partnered discovery programs.
Operations are anchored in Salt Lake City, with post-Exscientia capabilities adding precision chemistry design and automated synthesis. The company executes through scaled data generation and one consolidated operating segment rather than separate commercial product lines.
No approved medicines generate product revenue. Near-term revenue comes mainly from collaboration agreements, and the business depends on Recursion OS-enabled discovery, clinical validation, partner milestones, and regulatory progress across internal and partnered programs.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 17, 2026 | Morgan Stanley | Target | Target: $5.50 | Target: $5.30 |
| May 14, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $11 | Target: $5.50 |
| Dec 17, 2025 | UBS | Target | Target: — | Target: $11 |
| Dec 17, 2025 | Morgan Stanley | Target | Target: — | Target: $11 |
| Dec 17, 2025 | JP Morgan | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $545.7M · Total debt $61.9M · Total assets $1.21B · Shareholders' equity $915.0M
- Revenue
- $7.7M
- Operating income
- −$135.0M
- Net income
- −$131.0M
No dividends on record.
| Institutions | 68.38% | 366.07M shares | |
|---|---|---|---|
| 361 holders · as of Jun 30, 2026 | |||
| Insiders | 3.65% | 19.56M shares | |
| 13 holders · as of Sep 16, 2026 | |||
| Other | 27.97% | 149.71M shares | |
| remainder | |||
535.34M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 9.40% | 50.30M | as of Jun 30, 2026 |
Ark Investment Management LLCInstitution | 7.72% | 41.34M | as of Jun 30, 2026 |
State Street CorpInstitution | 6.48% | 34.71M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.82% | 31.13M | as of Jun 30, 2026 |
Baillie Gifford & CoInstitution | 4.39% | 23.49M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 8, 2026 | Najat Khan | director, officer: CEO and President | −22,408 | $3.52 |
| Sep 1, 2026 | Blake Borgeson | director | −30,000 | $3.34 |
| Aug 4, 2026 | Blake Borgeson | director | −30,000 | $3.25 |
| Jul 7, 2026 | Blake Borgeson | director | −40,000 | $3.96 |
| Jun 18, 2026 | Namandje Bumpus | director | −3,963 | $3.18 |
- Schrödinger
Computational platform and oncology-discovery peer
- Relay Therapeutics
Computational precision-medicine and oncology peer
- AbCellera Biologics
Antibody discovery platform and pipeline peer
- Roivant Sciences
Scalable biotech-platform and pipeline peer
- Moderna
mRNA platform peer across oncology and rare disease
- BioNTech (ADR)
Immunotherapy platform peer with late-stage oncology focus
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Recursion Pharmaceuticals | $4.05 | 0.00% | $2.08B | — | — | 38.0 | −61.8% |
| Schrödinger | $31.00 | +0.98% | $2.26B | — | — | 8.7 | +7.5% |
| Relay Therapeutics | $19.24 | −0.57% | $3.99B | — | — | 385.1 | −48.3% |
| AbCellera Biologics | $12.71 | +0.53% | $3.87B | — | — | 58.4 | −76.3% |
| Roivant Sciences | $38.33 | +0.29% | $28.17B | — | — | 3,739.6 | −33.6% |
| Moderna | $181.86 | −0.38% | $68.62B | — | — | 30.8 | +2.1% |
| BioNTech (ADR) | $100.87 | +0.07% | $24.62B | — | — | 8.1 | −60.7% |
| Median | — | — | 44.6 | −40.9% |